Fig. 6
CXCR2 ligands induce myeloid-derived suppressor cell infiltration. a Chemotaxis of mouse MDSCs, from subcutaneous tumor of HM-1 tumor-bearing mice, in response to CXCL1, CXCL2, and CXCL5; n = 4. b Chemotaxis of mouse MDSCs, from subcutaneous tumor of HM-1 tumor-bearing mice, pre-treated with SB265610 (CXCR2 antagonist) at each concentration in the presence of each CXCR2 ligands (at 100 ng/mL); n = 4. c Chemotaxis response of MDSCs, from human ovarian cancer ascites, to CXCL1, CXCL2, and CXCL5. The chemotaxis index is shown; n = 4. d Chemotaxis response of human MDSCs treated with SB265610 at each concentration in the presence of each CXCR2 ligands; n = 4. *P < 0.05, **P < 0.01, and ***P < 0.001 (one-way ANOVA with Tukey’s multiple comparisons test in a–d)
